TNFRSF17 and Miyoshi myopathy: A potential target molecular biomarker for MM therapy is the B-cell maturation antigen (BCMA), which is expressed in normal mature B cells and not in other tissues, overly expressed in multiple myeloma, and plays a role in disease severity, progression, and relapse [4,5,6].